Evotec And Novo Nordisk Launch First Projects For LAB EN2 Accelerator, Focusing On Cardiometabolic Diseases
Eli Lilly and Co (LLY.US) seeks to expand the indications for its weight loss medication and will conduct trials to treat addictive behaviors.
Eli Lilly and Co will test a weight loss drug for treating addiction in 2025.
BofA Restarts Coverage of 11 Large-cap Biopharmas
Novo Nordisk's Wegovy Sales Drop Is Temporary; Forecasts Still on Track -- Market Talk
Jim Cramer Is 'Not A Fan' Of Novavax, Says This Tech Stock Is 'Expensive'
Eikonizo Therapeutics Announces Investment by Novo Nordisk; Advancing Lead Candidate EKZ-102 Toward Clinical Development
